1.Downregulation of Ro60 inhibits migration and invasion of human lung adenocarci-noma A549 cells
Wan YAO ; Jilai LIU ; Pengda SUN ; Baolei TIAN ; Bin LIU ; Yi SONG ; Zhixian SUN
Military Medical Sciences 2016;40(3):213-216
Objective To study the effect of Ro60 on migration and invasion of lung adenocarcinoma A 549 cells. Methods We knocked down Ro60 and analyzed the ability of migration and invasion of A 549 cells.Quantitative real time ( RT)-PCR and Western blotting were performed to detect mRNA and protein levels of selected molecules associated with migration and invasion of neoplasm .Results When Ro60 was downregulated , the migration and invasion of A 549 cells decreased markedly.Meanwhile,the mRNA expression of matrix metalloproteinase (MMP)9,c-Src etc was observably reduced.Furthermore, downregulation of Ro60 diminished the expression of Src protein and the activation of MMP-9 protein.Conclusion Downregulation of Ro60 inhibits migration and invasion of A549 cells by regulating Src protein and activating MMP-9 protein.
2.Studies on the relationship of PDCD 4 with the invasion of astrocytic gliomas
Zhixian WAN ; Xiongwei WANG ; Yuanxun DONG ; Lei WANG ; Chunlei TIAN ; Xuguang WANG
Chongqing Medicine 2013;(32):3900-3901
Objective To investigate the relationship of programmed cell death 4(PDCD4) with the invasion of astrocytic glio-mas .Methods Using the immunohistochemical method to detect the expression of PDCD4 in astrocytic gliomas in different grades . Measuring the peritumoral low-density area on MRI scan ,then compared with the results of immunohistochemical expression .Re-sults The downregulation of PDCD4 was with the increasing of the malignant grade of astrocytic gliomas .The tumor grade malig-nancy was positively correlated with the grade of the peritumoral low-density area on MRI scan(P<0 .05) ,while the expression of PDCD4 was negatively correlated with the grade of astrocytic gliomas (P<0 .01) .Conclusion PDCD4 might serve as one of the in-dicators of invasion and malignant phenotype for astrocytic gliomas .
3.An experimental research on effect of LTβR and P65 in progression of bladder cancer
Xiuzhi DUAN ; Mo SHEN ; Xiucui HAN ; Xiuling WU ; Li WAN ; Zhiliang WENG ; Longjie SHEN ; Yinghe CHEN ; Jian CAI ; Zhixian YU ; Yuancui ZHENG ; Zhihua TAO
Chinese Journal of Laboratory Medicine 2012;35(5):436-442
ObjectiveTo investigate the relationship of lymphotoxin β receptor (LTβR) and classical nuclear factor-κB (NF-κB) activation pathway in the pathogenesis and progress of cystitis and bladder cancer.MethodsThe LTβR and P65 mRNA expression were detected by Real-time quantitative PCR in 108 cases of fresh bladder tissue specimens (75 cases of bladder cancer,10 cases of inflammation and 23 normal bladder mucosa cases grouped by the tissue classification ),and protein expression were analyzed by immunohistochemistry assay in 118 cases of paraffin-embedded biopsy specimens (73 cases of bladder cancer,30 cases of cysitis and 15 normal bladder mucosa cases).The correlation analysis between the expressions of LTβR and P65 with clinical pathological data was then performed.Differences between LTβR and P65 mRNA and protein expression level were compared in different groups of bladder tissues using Kruskal-Wallis H test and the Chi-square test.Results( 1 )The mRNA expressions of LTβR and NF-κB/P65were higher in bladder cancer than those in normal group ( LTβR:29.4 ( 14.2 - 46.7 ) × 10 - 3/1.2 ( 0.3 -7.0) ×10-3,Z=-5.508; P65:9.7 (2.7 -21.1) ×10-3/1.0(0.8 ~1.8) ×10-3,Z=-5.030,P<0.05 ).There were significantly differences between bladder cancer with different histological grades ( LTβR:18.2(2.1-31.3) × 10-3/ 28.4(16.6-36.2) × 10-3/47.9(34.3 -70.5) ×10-3,x2K-W=20.378;P65:4.9(1.3 - 12.0) × 10-3/7.4(3.0-21.9) × 10-3/17.0(10.0 ~28.3)× 10-3 ,x2K-W2 =15.219,P all <0.05) and lymph node metastasis (LTβR:27.2(9.7-40.1) ×10-3/39.4(26.7 -52.6) ×10-3,Z=-2.552; P65:7.4(2.3-15.6) ×10-3/13.4(6.7-23.3) ×10-3,Z=-2.026,P<0.05).(2)The positive rates of LTβR and phosphorylated P65 ( p-P65 ) protein in cancer were higber than those of normal group (LTβR:69.8%/13.3%,x2 =16.600 ; p-P65:56.2%/6.7%,x2 =12.220,P < 0.05 ).Upregulation of LTβR and p-P65 were associated with the histological grade (LTβR:56.3%/70.0%/90.4%,x2 =7.055; p-P65:40.6% /60.0%/76.2%,x2 =6.679,P <0.05) and with lymph node metastasis (LTβR:58.3%/92.0%,x2 =8.849; p-P65:52.1%/64.0%,x2 =5.088,P <0.05).(3)There was a positive correlation between LTβR and P65 expression ( mRNA:r =0.654,P < 0.05,protein:r =0.399,P < 0.05 )in the bladder cancer and cystitis (r =0.521,P<0.05).ConclusionsThe activation of LTβR and P65 was associated with progression and metastasis of bladder cancer.The activation of classical NF-κB pathway by LTβR may be achieved by P65.
4.A Meta-analysis on the outcome of Solid Hemangioblastomas treated by surgery combined with preoperative endovascular embolization
Xiangji LI ; Yanting LIU ; Zhixian WAN ; Yuefeng ZHU ; Chunlei TIAN
Journal of Clinical Surgery 2023;31(12):1130-1133
Objective To evaluate the clinical efficacy and safety of preoperative endovascular embolization of Solid Hemangioblastomas.Methods The data bases including Wan Fang,CNKI(China National Knowledge Infrastructure),VIP Database,PubMed、Medline、Springer were searched for the related studies.Two independent surgeons assessed trails for eligibility and quality,and all data marching the standards were abstracted for Meta-analysis by RevMan 5.3.Results 8 randomized controlled trails(RCT)were included.Selected analysis of embolized and non-embolized groups of Solid Hemangioblastomas were observed for variables of clinical efficacy in surgery time,number of blood loss and transfusions,complete resection,there were statistical difference.(P<0.000 01,WMD=-1.18,95%CI[-1.16,-0.71];P<0.000 01,WMD=-464.17,95%CI[-492.17,-437.24];P<0.000 01,WMD=-238.81,95%CI[-282.84,-194.77];P<0.006,RR=1.17,95%CI[1.05,1.31]).Conclusion The preoperative endovascular embolization is beneficial for Hemangioblastomas because it can shorten the time of surgery,diminish the necessity of intra-operative blood loss and transfusion,it also raises the ratio of complete resection of Solid Hemangioblastomas.
5.Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis.
Qing WANG ; Zhaoliang XIE ; Nansheng WAN ; Lei YANG ; Zhixian JIN ; Fang JIN ; Zhaoming HUANG ; Min CHEN ; Huiming WANG ; Jing FENG
Chinese Medical Journal 2023;136(11):1278-1290
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterized by progressive lung fibrogenesis and histological features of usual interstitial pneumonia. IPF has a poor prognosis and presents a spectrum of disease courses ranging from slow evolving disease to rapid deterioration; thus, a differential diagnosis remains challenging. Several biomarkers have been identified to achieve a differential diagnosis; however, comprehensive reviews are lacking. This review summarizes over 100 biomarkers which can be divided into six categories according to their functions: differentially expressed biomarkers in the IPF compared to healthy controls; biomarkers distinguishing IPF from other types of interstitial lung disease; biomarkers differentiating acute exacerbation of IPF from stable disease; biomarkers predicting disease progression; biomarkers related to disease severity; and biomarkers related to treatment. Specimen used for the diagnosis of IPF included serum, bronchoalveolar lavage fluid, lung tissue, and sputum. IPF-specific biomarkers are of great clinical value for the differential diagnosis of IPF. Currently, the physiological measurements used to evaluate the occurrence of acute exacerbation, disease progression, and disease severity have limitations. Combining physiological measurements with biomarkers may increase the accuracy and sensitivity of diagnosis and disease evaluation of IPF. Most biomarkers described in this review are not routinely used in clinical practice. Future large-scale multicenter studies are required to design and validate suitable biomarker panels that have diagnostic utility for IPF.
Humans
;
Idiopathic Pulmonary Fibrosis/diagnosis*
;
Biomarkers
;
Lung Diseases, Interstitial
;
Lung
;
Bronchoalveolar Lavage Fluid
;
Disease Progression
;
Prognosis